Eloxx Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-6.0M | $-3.1M | $-17.1M | $-36.1M | $-66.7M | $-34.6M | $-50.9M | $-47.2M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $0 | $35.0K | $113.0K | $77.0K | $114.0K | $68.0K | $87.0K | $216.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $235.0K | $541.0K | $2.0M | $3.0M | $9.2M | $8.7M | $11.3M | $13.4M |
| Net Cash from Operating Activities | $-6.3M | $-4.7M | $-14.3M | $-31.8M | $-35.0M | $-28.2M | $-39.4M | $-31.4M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | $66.0K | $89.0K | — | $40.0K | $235.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $1.0K | $38.0K | $309.0K | $-66.0K | $2.1M | $33.8M | $-33.5M | $-317.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | $0 | $0 |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $11.0M | $3.4M | $-4.1M | $8.8M | $50.8M | $-3.4M | $46.8M | $56.2M |
| Net Change in Cash | $4.7M | $-1.2M | $-18.1M | $-23.1M | $17.8M | $2.2M | $-26.1M | $24.5M |
| Free Cash Flow | — | — | — | $-31.9M | $-35.1M | — | $-39.4M | $-31.6M |